Personalized ADC therapy for advanced solid tumors
Treatments studied
Part of Cancer clinical trials.
This trial tests personalized antibody-drug conjugates (ADCs) for advanced solid tumors. It looks for specific proteins on your tumor cells to match you with a treatment that targets them directly.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have an advanced or metastatic solid tumor that is not curable with standard treatments.
- You need to have a tumor tissue sample tested for certain proteins (like Trop-2, Nectin-4, or HER2) to see if you qualify.
- You must be willing to have a biopsy of your tumor before and during the study.
- You should have had no more than 3 prior chemotherapy treatments for advanced cancer.
- You need to be in fairly good health (able to do daily activities) with adequate organ function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study matches people with advanced solid tumors to targeted treatment plans based on genetic testing. It also requires tumor sample testing to help doctors choose the most promising therapy for your specific tumor changes.
This study is for people with advanced breast, bladder, lung, or stomach cancer who are about to start treatment with a type of targeted therapy called an antibody-drug conjugate (ADC). The trial will collect tumor samples and blood to understand how cancers become resistant to these drugs and to find better ways to predict treatment success.
This study tests a new type of targeted therapy called an antibody-drug conjugate (ADC) for advanced breast cancer that is hormone-receptor-positive and HER2-negative. It is for people whose cancer has progressed after CDK4/6 inhibitor treatment, and may offer a new option to slow tumor growth.
This trial tests a new medicine that targets cancer cells with specific proteins, to see if it can stop the growth of advanced pancreatic and breast cancer when other treatments have stopped working. It is an umbrella study, which means different protein-matched drugs are tested for different cancer types.
This trial tests whether FDA-approved targeted drugs can help people with advanced cancer whose tumors have specific gene changes. It aims to match your tumor's unique genetic profile to a drug that may work better for you.
This study looks at whether giving a different antibody-drug conjugate (ADC) after a previous one can help people with advanced or metastatic breast cancer. It aims to find new options for patients who have already had ADC treatment.
Hear when a new Metastatic Malignant Solid Neoplasm trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.